Arkolith/Insider Trading/BBIO/Form 4

Kumar Neil

Chief Executive Officer, DirectorBridgeBio Pharma, Inc. (BBIO) · full profile →Form 4 · filed May 26, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.8M
Net Open-Market Flow
-$1.8M
Transactions
5
5 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 21, 2026Sell(S)2K$67.57$152K267K
May 21, 2026Sell(S)7K$68.30$459K260K
May 21, 2026Sell(S)5K$69.22$351K255K
May 21, 2026Sell(S)11K$70.48$793K244K
May 21, 2026Sell(S)800$70.92$57K243K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001470831-26-000488) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML